# JUDGE — L4-TICK5-K3RES, iteration 1

Judge: Kimi K3 (≠ author; Conductor edited, TICK5-K3RES.md is labeled "not a KEEP" — not treated as evidence).
Date: 2026-09-02. Mood: critic. Files read in full (body + sources YAML), not via tick log.

## Independent re-fetches this judging run

| Source | What the fetch showed (this run) |
|---|---|
| efetch PMID 40544433 | REDEFINE 1, NEJM 2025;393(7):635-647, doi:10.1056/NEJMoa2502081, NCT05567796. n=3417 (2108/302/302/705). "estimated mean percent change in body weight … week 68 was -20.4% with cagrilintide-semaglutide … -3.0% with placebo (estimated difference, -17.3 percentage points; 95% CI, -18.1 to -16.6)". Estimand: treatment-policy. **"22.7" appears nowhere in the abstract.** |
| FDA 2025 First Generic Drug Approvals | Row 71: ANDA 214568, Liraglutide Injection, Teva Pharmaceuticals Development Inc., RLD Saxenda Injection, approval date 8/27/2025. (The ANDA indication cell contains the 60 kg pediatric cutoff — the blog does not copy it.) |
| Drugs@FDA ApplNo=217806 | NDA 217806 = ZEPBOUND (tirzepatide), Eli Lilly; ORIG-1 11/08/2023. Supplements table row: **SUPPL-13, action date 12/20/2024, "Efficacy-New Indication"** — exactly as claimed. |
| efetch PMID 38912654 (extra, critic's spot-check) | SURMOUNT-OSA, NEJM 2024, NCT05412004. Trial 1 AHI −25.3 vs −5.3, ETD −20.0 (−25.8 to −14.2); Trial 2 −29.3 vs −5.5, ETD −23.8 (−29.6 to −17.9). Matches the blog's tables. |
| efetch PMID 26132939 (extra — blog stamps verifiedAt 2026-09-02) | SCALE, NEJM 2015, NCT01272219, doi:10.1056/NEJMoa1411892. n=3731; week 56 −8.4 kg vs −2.8 kg, diff −5.6 (−6.0 to −5.1); 63.2% vs 27.1% ≥5%. Matches the blog bullet and source YAML exactly. |

## Claim-by-claim score

| # | Claim | Verdict | Evidence |
|---|---|---|---|
| 1 | "over 15,000" STEP enrollment and "14 indications" stripped | **PASS** | Grep of all three files for `15,?000\|14 indications\|over 15`: zero hits. best-peptide line ~124 now carries an honest substitute: "This page does not quote a program-wide enrollment total." |
| 2 | REDEFINE-1 attached at treatment-policy −20.4% vs −3.0%; 22.7% stripped | **PASS** | Blog quotes −20.4/−3.0, ETD −17.3 (−18.1 to −16.6), n=3417, labeled treatment-policy — matches my efetch byte-for-byte in substance. 22.7% absent from abstract and absent from all three files (grep). Blog dates the absence: "abstract fetched 2026-09-02 does not report a trial-product percent." Correct paper, not a REDEFINE-2 sibling mixup (NCT05567796 matches YAML). |
| 3 | ANDA 214568 Teva/Saxenda 2025-08-27 attached; no kg cutoff copied | **PASS** | Blog: "ANDA 214568 (Teva, liraglutide injection referencing Saxenda) … action date 27 August 2025 … a regulatory listing, not a new efficacy trial." Matches FDA row 71. Grep `60 kg`: zero hits — the ANDA's pediatric weight cutoff was NOT imported. No dosing language added. |
| 4 | Drugs@FDA NDA 217806 SUPPL-13 2024-12-20 Efficacy-New Indication | **PASS** | Live Drugs@FDA shows exactly that row. Zepbound blog line ~68 states it verbatim with citation; source YAML `drugsfda-zepbound-217806` URL resolves to the same page, verifiedAt 2026-09-02. |
| 5 | oveporexton metaDescription no longer "Updated Feb 2026" | **PASS** | Frontmatter now reads "Updated Sep 2026." |

## L4 loop bar (LOOPS.md §L4 success + judge fail list)

- Identifier provenance: **PASS** — all three new identifiers were in the tick's fetch table; I re-resolved each live, topical match confirmed (not resolution-only).
- Estimand discipline: **PASS** — treatment-policy leads on REDEFINE-1; efficacy-estimand 22.7% excluded with a dated note; SURMOUNT-5 bullet already names its estimand context.
- Absence claims dated: **PASS** — "fetched 2026-09-02", "as of 2026-09-01", "17 August 2026" throughout.
- No fabricated figure: **PASS** — every number I re-fetched (REDEFINE-1, SCALE, SURMOUNT-OSA primaries/ETDs) matches its abstract.
- Banned content: **PASS** — no kg cutoffs, no dosing protocol, no sourcing language; banned-figure grep (63% OSA, 28.7% TRIUMPH) clean across all three files.
- No self-KEEP / wrapper trust: n/a to content, and the tick note explicitly disclaims KEEP.

## L6 check (no new URL / no invented figures)

- `git status --short` on the three paths: all `M`, all pre-existing slugs. **No new blog URL. Net URL delta 0. PASS.**
- No invented figures: PASS per the fetch table above. `lastUpdated` bumped to 2026-09-02 on all three files.

## Observations (not fails)

1. `pmid-26132939` (SCALE) carries `verifiedAt: '2026-09-02'` in best-peptide's YAML but is absent from TICK5-K3RES.md's fetch table. I re-fetched it; all quoted numbers match the abstract, so no live false fact — but the tick note should list every id stamped that day. Documentation gap, not gaming.
2. SURMOUNT-OSA secondary-table figures (−50.7%/−3.0%, 42.2%/15.9%, etc.) are not in the PubMed abstract; they trace to the NEJM key-secondary table / FDA press framing, and the blog says exactly that with a fetch date. Verifier should still re-resolve per protocol at Wave 3.
3. LEADER remains named without a PMID — pre-existing, disclosed in the tick's "Not done," not introduced this tick. Stays on the residual worklist.

## Gaming check

The metric here is "numbers on the page trace to a fetched source," and it was not gamed: the implementer removed two impressive-but-uncited claims (15,000 enrollment; 14 indications) rather than laundering them, declined the ANDA's kg-cutoff language even though the fetched page offered it, and replaced the stripped 22.7% with a dated no-quote note instead of a vaguer superlative — all moves that make the pages *less* flashy, which is the opposite of proxy-chasing. The tick note disclaims KEEP and asks for this judgment. The one soft spot (SCALE's verifiedAt stamp missing from the fetch table) survives scrutiny because my independent fetch confirms the figures; it is recorded above as a documentation omission, not silently excused.

## Verdict

**KEEP.** All five claimed changes verified against live re-fetches; zero fail-list hits; no new URLs; no invented figures; banned-content grep clean. Residual items (LEADER citation, Wave-3 identifier re-resolution) pass to the Verifier/Conductor worklists unchanged.
